Albany, New York, March 29, 2017: MarketResearchReport.biz has announced the addition of a market intelligence report, titled “Global Human Respiratory Syncytial Virus Drugs Market 2016-2020,” to its wide repository. The report offers an immaculate understanding of the various parameters of the market, including its dynamics, competitive scenario, drug category, geographical segmentation.
As per the findings of the report, the global human respiratory syncytial virus (RSV) drugs market is expected to expand at a steady CAGR of more than 4% from 2016 to 2020. The growing adoption of novel diagnostic tools is fostering the growth prospects of the market. The soaring need for accurate diagnosis is paving way for increased research and development of new and effective diagnostic tools. Some of the novel diagnostic methods are RT-PCR assays, rapid diagnostic assays, and serological tests. Moreover, the expanding base of patient population suffering from RSV is providing a significant boost to the growth of the market.
On the other hand, the protean healthcare guidelines are negatively impacting the growth of the market. Furthermore, the availability of a limited number of drugs is leading to low penetration rates, which in turn is hampering the growth of the market. Nevertheless, the increasing research activities in emerging economies for the development of novel RSV drugs are likely to augment the market in the near future.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/902730
Based on drug category, the global human RSV drugs market is bifurcated into off-label drugs and approved drugs. Approved drugs will represent a larger share in the revenue pie in the market throughout the forecast period. The expected launch of several biologics such as RNAi therapeutics, vaccines, and monoclonal antibodies. On the basis of geography, the market is divided into Europe, the U.S., and Rest of the World (RoW). The RoW segment will continue to account for the lion’s share in the market in terms of revenue until 2020. The increasing prevalence of RSV infections and the improving healthcare infrastructure in emerging countries such as India, Brazil, China, and South Africa.
Vendors offering Synagis in their respective markets are typically the major revenue contributors in the global human respiratory syncytial virus drugs market. Mergers and acquisitions are commonly adopted strategies by key players to improve their pipelines and consolidate their presence in the market. Several players are paying high attention to research and development activities in order to introduce RSV vaccines for individuals above 60 years of age.
The leading players in the global human RSV drugs market are GSK, Abbvie, Teva Pharmaceutical, and AstraZeneca. Some other prominent companies operating in the market are ADMA Biologics, Ark Biosciences, Boehringer Ingelheim, Aviragen Therapeutics, ImmunoVaccine Technologies, Kyowa Hakko Kirin, Johnson & Johnson, Medivir, Mymetics, Mucosis, Regeneron Pharmaceuticals, Novavax, ReViral, and Vaxart.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com